Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dasatinib
Drug ID BADD_D00589
Description Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
Indications and Usage For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
Marketing Status approved; investigational
ATC Code L01EA02
DrugBank ID DB01254
KEGG ID D03658; D06414
MeSH ID D000069439
PubChem ID 3062316
TTD Drug ID D0E6XR
NDC Product Code 0003-0857; 53104-7725; 0003-0852; 68554-0070; 0003-0528; 59651-468; 54893-0015; 62207-973; 63285-863; 63285-866; 0003-0855; 63285-867; 0003-0527; 14778-1313; 50193-0524; 54893-0047; 63285-862; 0003-0524; 63285-864; 63285-865
UNII RBZ1571X5H
Synonyms Dasatinib | N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | Sprycel | (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | BMS 354825 | 354825, BMS | BMS354825 | BMS-354825
Chemical Information
Molecular Formula C22H26ClN7O2S
CAS Registry Number 302962-49-8
SMILES CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysphonia19.19.03.002; 17.02.08.004; 22.12.03.006--
Dyspnoea02.11.05.003; 22.02.01.0040.034776%
Dyspnoea exertional02.11.05.005; 22.02.01.0050.001713%Not Available
Ear disorder04.03.01.0010.000627%Not Available
Ear haemorrhage04.03.01.002; 12.01.14.004; 24.07.01.004--Not Available
Ear pain04.03.01.0030.000358%
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Eczema23.03.04.0060.000795%
Electrocardiogram13.14.05.037--Not Available
Electrocardiogram QT prolonged13.14.05.004--
Emphysema22.01.02.0020.000224%Not Available
Enteritis07.08.03.0020.000280%
Enterocolitis07.08.03.0030.000918%
Enterocolitis haemorrhagic24.07.02.006; 07.08.01.0070.001567%Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.0030.000571%
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythema nodosum10.02.01.020; 23.07.02.0010.000112%Not Available
Essential hypertension24.08.02.0080.000246%Not Available
Eye discharge06.04.05.0010.000381%Not Available
Eye disorder06.08.03.001--Not Available
Eye haemorrhage24.07.05.002; 06.07.02.001; 12.02.02.0120.000828%Not Available
Eye swelling06.08.03.0030.003761%Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.0040.000739%Not Available
Face oedema08.01.07.003; 23.04.01.004; 10.01.05.0020.001321%
Facial pain08.01.08.0120.000571%
Facial paralysis17.04.03.008--Not Available
Faeces discoloured07.01.03.0020.001477%Not Available
Faeces hard07.01.03.0030.000627%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene